Are we using and monitoring thiopurines and biologics optimally?

Peter M. Irving*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

The use of biologics and thiopurines in patients with inflammatory bowel disease has increased rapidly over the last 2 decades with both classes of drugs being used more frequently and earlier in the disease course. This vogue has come about through a realisation that for some patients Crohn's disease and ulcerative colitis are progressive diseases and that use of these therapies can sometimes prevent that progression. However, knowledge about the optimal way in which to use these drugs continues to evolve. In this paper, the evidence regarding optimal timing and dosing of thiopurines and biologics will be reviewed as will the role of thiopurine methyltransferase testing along with therapeutic drug monitoring of both thiopurines and biologics. In addition, possible future applications of biologic drug level and anti-drug antibody testing will be considered.

Original languageEnglish
Pages (from-to)410-418
Number of pages9
JournalDigestive Diseases
Volume32
Issue number4
DOIs
Publication statusPublished - Jun 2014

Keywords

  • Adalimumab
  • Drug levels
  • Inflammatory bowel disease
  • Infliximab
  • Thiopurines

Fingerprint

Dive into the research topics of 'Are we using and monitoring thiopurines and biologics optimally?'. Together they form a unique fingerprint.

Cite this